

PK3065US3

6

**ELECTION OF SPECIES**

In response to the Examiner's communication dated 4 June 2001, requesting an election of species, Applicants hereby elect a peptide of the sequence EGPTLRQWL (SEQ ID NO:5). Claims readable thereon are claims 1-4 and 11-27. Applicants appreciate the Examiner's notation that upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species, as provided by 37 CFR 1.141.

**REMARKS**

New claims 19-27 are supported by the specification and claims as originally filed.

Claim 19 recites a peptide comprising the sequence IEGPTLRQWL (SEQ ID NO:5), and claim 20 recites a dimer of two such peptides. This sequence is described in the specification as filed, e.g., at page 8, lines 4-9; page 35, lines 24-29. Dimers of peptides containing this sequence are described in Tables 7, 9 and 10.

Claims 21 - 24 recite a compound of claim 19 or 20 attached to a non-proteinaceous polymer, which is described in the specification e.g., at page 44, lines 22-30.

Claims 25-26 recite that the dimers of claims 20 and 22 are joined via a K residue, see e.g., Example 9 at page 77 and Table 7.

PK3065US3

7

Claim 27 recites a dimer of two sequences, each sequence comprising  
IEGPTLRQWLAARA (SEQ ID NO:17); see e.g., the specification at Example 9 and  
Table 7.

Respectfully submitted,



Virginia G. Campen  
Attorney of Record  
Registration No. 37,092

Date: 18 Nov. 04  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919) 483-1012  
Facsimile: (919) 483-7988